Life-science and biotech investing is our focus in Biotech Frontiers… Some startups follow a clear, smooth path to success. Others skyrocket, then quickly fall back to Earth. But, generally speaking, as a sector, biotech stocks perform differently than tech stocks, “forever stocks,” and certainly the blue chips… Biotech veteran Erez Kalir heads up this advisory that publishes on the first Friday of each month, with regular unscheduled updates as they are needed.
Issues & Updates
-
In Good Company… at a Fraction of the Price
This report highlights the opportunity to invest alongside the world’s most sophisticated investors at a significant discount to the prices they paid – while the company we feature is not yet a household name.
-
Two Companies, Two Blowout Reports
With a 64% probability of the Fed cutting interest rates in September, the macro economic environment is clearly shifting in the right direction for biotech, but even before that has happened, these two companies released blowout earnings reports.
-
Outsmarting Big Pharma
This month’s issue of Biotech Frontiers focuses on a fast follower whose stock is poised to soar because it has a better version of a successful medicine… which it has also, strategically, chosen to make available at a better price.
-
The Drugmaker’s Hidden Jewel
In this month’s issue, we focus on a drugmaker that has one hidden asset that ties all its other assets together and acts as a value multiplier for them: and it has a spectacular track record of success that traces back to the company’s origins.
Special Reports
America’s Last Election
